{"id":"W2981636558","doi":"10.1016/j.jtho.2019.10.013","title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke; University of Alberta","funders":"Takeda Oncology; EMD Serono; National Institutes of Health; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; Clovis Oncology; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Genzyme; Takeda Pharmaceuticals U.S.A.; Foundation Medicine; United Therapeutics Corporation; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Purdue University; MedImmune; Sanofi; GlaxoSmithKline; Roche; AbbVie; Genentech; Aeglea BioTherapeutics; Amgen; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Moderna; Pfizer; AstraZeneca; Purdue Pharma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Oncology; Placebo; Clinical endpoint; Population; Gastroenterology; Confidence interval; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003841329,0.0003317407,0.002970163,0.0005660837,0.0001700839,0.00001786989,0.0002227827,0.0002006233,0.000323972],"category_scores_gemma":[0.001961002,0.0002158946,0.0004751708,0.0003289203,0.0005048514,0.0002489254,0.0001812545,0.0005559537,0.000004472546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008884407,"about_ca_system_score_gemma":0.001509733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007480133,"about_ca_topic_score_gemma":0.00005304083,"domain_scores_codex":[0.9960935,0.001083913,0.001347839,0.000358822,0.0006875956,0.0004283924],"domain_scores_gemma":[0.9918698,0.004976104,0.001444494,0.0003452272,0.001084769,0.0002795789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9454451,0.002561261,0.0003535889,0.0003066671,0.007499869,0.0001587589,0.006320353,0.00003140644,0.007330481,0.00001521511,0.002481973,0.02749536],"study_design_scores_gemma":[0.8778419,0.09849394,0.001675581,0.0002832824,0.002517707,0.0002117804,0.01239341,0.001101416,0.001538014,0.0002164456,0.003465723,0.0002607692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980163,0.009803067,0.000197781,0.002209798,0.001006075,0.00413379,0.00004482106,0.00001436981,0.002427277],"genre_scores_gemma":[0.9945428,0.001300084,0.000888397,0.0003230718,0.000256507,0.0001166232,0.00001392191,0.00003985228,0.002518788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09593268,"threshold_uncertainty_score":0.8803927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253425639402656,"score_gpt":0.5412142173577857,"score_spread":0.4158716534175201,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}